B
APGE

Braidwell’s Apogee Therapeutics APGE Stock Holding History

Braidwell’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-478,667
Closed -$40.3M – 87
2026
Q1 		$40.3M Sell
478,667
-96,400
-17% -$7M 1.34% 29
2025
Q4 		$43.4M Sell
575,067
-863,678
-60% -$54.4M 1.39% 29
2025
Q3 		$57.2M Sell
1,438,745
-39,767
-3% -$1.52M 1.7% 20
2025
Q2 		$64.2M Sell
1,478,512
-61,850
-4% -$2.35M 2.2% 18
2025
Q1 		$57.5M Hold
1,540,362
– – 2.02% 20
2024
Q4 		$69.8M Sell
1,540,362
-102,864
-6% -$5.25M 2.07% 15
2024
Q3 		$96.5M Sell
1,643,226
-748,816
-31% -$35.9M 2.74% 9
2024
Q2 		$94.1M Buy
2,392,042
+549,527
+30% +$26.7M 2.95% 8
2024
Q1 		$122M Buy
1,842,515
+1,161,414
+171% +$50.7M 3.95% 5
2023
Q4 		$19M Buy
681,101
+189,988
+39% +$3.81M 0.7% 42
2023
Q3 		$10.5M Buy
+491,113
New +$10.8M 0.33% 75

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return

Braidwell's APGE Position: Q2 2026 in Review

Braidwell sold out of Apogee Therapeutics (APGE) in Q2 2026, closing a stake of 478,667 shares — an estimated $40.3M sold.

Braidwell first reported a position in APGE in Q3 2023 and held it in 11 quarters. The position peaked at $122M in Q1 2024. 289 funds tracked by Wall St. Rank hold APGE as of Q2 2026.

  • Braidwell reported no remaining Apogee Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Braidwell sold 478,667 Apogee Therapeutics shares in Q2 2026, an estimated $40.3M.
  • Braidwell first reported a position in Apogee Therapeutics in Q3 2023 and held it in 11 quarters.
  • Braidwell's Apogee Therapeutics position peaked at $122M in Q1 2024.
  • 289 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q2 2026.

Based on Braidwell's 13F filing for Q2 2026, filed 14 Aug 2026.